The PI3K/AKT/mTOR pathway is activated through multiple mechanisms in colorectal carcinoma (CRC).
INTRODUCTION
The phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is activated in colorectal carcinoma (CRC) through various mechanisms including missense mutations in PIK3CA and AKT1 (v-akt murine thymoma viral oncogene homologue 1), and loss of PTEN expression. The PIK3CA gene encodes the p110ɲ catalytic subunit of PI3K. Its activation promotes carcinogenesis through increased cell proliferation and survival.
1 80% of oncogenic mutations in PIK3CA are clustered at hotspots in exon 10 at codons 542 and 545 and exon 21 at codon 1047. 2 Recently, proximal location and mucinous histology have been associated with PIK3CA mutant CRC. 3 Differences between the molecular profiles of PIK3CA exons 10 and 21 mutant CRC include a higher prevalence of concurrent KRAS mutation with PIK3CA exon 10 mutation and higher prevalence of BRAF co-mutation and microsatellite instability with PIK3CA exon 21 mutation. 4 In 2007, Carpten et al first described the pleckstrin homology domain missense mutation AKT1
E17K in various types of human and mouse tumors including breast, colorectal, ovarian, and myeloid malignancies. 5 Mutant Akt (E17K) is more readily ubiquitinated and phosphorylated than wild type Akt.
The ubiquitinated-phosphorylated-Akt (E17K) translocates more efficiently to the nucleus than wild type Akt, which may contribute to the transforming potential of E17K-Akt6. 6 Kumar et al have shown that the oncogenic effects of AKT1 E17K mutation may be due to rapid conformational changes affecting activation status. 7 Activation of the protein encoded by the gene occurs via membrane localization, which is mediated by the pleckstrin homology domain, and followed by the subsequent phosphorylation of AKT1 at S473 and T308 positions. 8 Unlike PIK3CA and PTEN alterations, AKT1 mutations have not been thoroughly studied in CRC due to low numbers, although past studies have identified rare cases. While previous studies have identified rare cases, analysis of characteristics including mutation prevalence, histopathologic features, concurrent driver mutations, and MSI status have not been performed. In this study, we aimed to characterize the clinicopathologic, molecular, and pathway activation status of the AKT1 pleckstrin homology domain hotspot mutation E17K and to compare these cases to PIK3CA mutants in a large cohort of CRC.
METHODS

Patients
After approval from the local Institutional Review Board, data were reviewed for a total of 2,631
CRC consecutively submitted for clinical molecular testing at MSKCC from 2009-2013. Testing was primarily to assess eligibility for anti-EGFR antibody therapy. Therefore, the vast majority of cases had distant metastases. An additional 491 cases with mutational analysis were identified through the cBio portal from The Cancer Genome Atlas (TCGA). 9 All 141 CRC cases with AKT1 p. E17K, PIK3CA p.R88Q, P.E542K, p.E545K/G/D, or PIK3CA p. H1047L/R were included for further histopathologic, molecular (including RAS/ RAF status), immunohistochemical, and clinical review.
Histopathology Review
World health Organization definitions were used to classify histopathology: mucinous histology was defined as ш50% of tumor volume comprised of extracellular mucin. Moderately differentiated CRC was defined as 50 to 95% of tumor volume comprised of glands. Poorly differentiated CRC was defined as <50% of tumor volume forming glands.
10
Mutation detection
Genomic DNA was extracted from formalin-fixed paraffin-embedded tumor tissue after macrodissection using the DNeasy Tissue kit (Qiagen, Valencia, CA), following the manufacturer's standard protocol. All cases were analyzed with the MassARRAY system (Sequenom) with primers as were used for DNA amplification. The PCR products were then separated by capillary electrophoresis.
The presence of additional peaks forming a second Gaussian distribution in ш2 of the 5 loci was interpreted as microsatellite instability-high (MSI-H).
PTEN and p-PRAS40 Immunohistochemistry
Immunohistochemical staining was performed for PTEN (1:100, Cell Signaling) and phospho-PRAS40 (1:40, Cell Signaling) as previously described 13 on cases with AKT1 E17K, PIK3CA exon 10 mutations, or PIK3CA exon 21 mutations for which formalin-fixed paraffin-embedded tissue was available.
Statistical Analysis
Statistical analyses were performed with chi square for 2x2 categorical analyses. Two-tailed p values between 0.01 and 0.05, and those less than 0.01 were reported separately to account for multiple hypothesis testing. Table 2 .
AKT1 E17K
All 18 institutional AKT1 E17K cases had distant metastases. The site tested was primary tumor for 12 (67%) and distant metastasis for 6 (33%) cases. AKT1-mutated CRC was significantly associated with mucinous morphology (p=0.0006) compared to PIK3CA-mutated CRC. Comparing exon-specific subsets, AKT1 mutants, like PIK3CA exon 21 mutants, were more likely to have mucinous differentiation and BRAF V600E co-mutation than PIK3CA exon 10 mutants (p=0.0001).
Of the 18 AKT1 E17K cases, 15 (83.3%) cases had concurrent RAS/ RAF activating mutations in the same sample including 6 (33.3%) KRAS exon 2 mutations, 5 (27.8%) BRAF V600E mutations, 2 (11.1%) KRAS exon 4 mutation, 1 (5.9%) NRAS exon 3 mutation, and 1 (5.9%) case with both a KRAS exon 2 and an NRAS exon 3 mutation. The mutation status of the last case was confirmed by repeat extraction and Sanger sequencing. In four patients, material was available to correlate the AKT1 status of both primary and metastasis. All 4 patients had the same RAS/RAF activating mutation in the primary and metastasis. Three of these 4 patients had AKT1 E17K mutations in both primary and metastasis. Interestingly, the fourth patient harbored an AKT1 E17K mutation (concurrent with KRAS) in a liver metastasis and a PIK3CA E542K mutation in the primary tumor (with the same KRAS mutation). These findings are suggestive of convergent, or parallel, evolution in the PI3K pathway.
14 Two patients with AKT1 E17K mutations who had wild type KRAS and BRAF received cetuximab, and both demonstrated primary resistance.
Three additional AKT1 E17K mutated cases were identified via the cBioPortal of TCGA, among 491 total CRC. One case had mucinous features and harbored a BRAF V600E mutation. The other two cases were moderately differentiated, one with a BRAF V600E mutation and the other with a KRAS A146T mutation.
PIK3CA exon 10
Seventy of 82 (85.4%) PIK3CA exon 10 mutations including E542K (32), E545K (44), E545G (5), E545D (1) were identified in stage IV patients. The site tested was the primary tumor for 51 (62.2%) and distant metastasis for 31 (37.8%) cases. Primary tumors were located in the proximal colon (n=32, 39.0%), transverse (n=8, 9.8%), and distal colon (n=42, 51.2%). In comparison to PIK3CA exon 21 mutants, these cases less frequently had poor differentiation (p=0.007) and more frequently had hepatic metastases (p=0.0001). 
PIK3CA R88Q
The clinicopathologic features of the 9 PIK3CA mutation R88Q are summarized in table 1. Five patients were stage IV. Four patients had liver metastases and 2 had intra-abdominal metastases. The site tested was primary tumor for 4 patients and metastasis for 5 patients. Only 3 patients (33%) in this group also harbored a RAS/RAF mutation. These included 2 KRAS exon 2 mutations and 1 KRAS exon 4 mutation. This contrasts with the helical and kinase domain PIK3CA mutants as well as the AKT1 E17K mutants, which had RAS/ RAF driver mutations in over 70% of cases.
DISCUSSION
This study is the first to characterize the clinical, pathologic, molecular, and pathway activation properties of CRC harboring AKT1 E17K mutations, with comparison to PIK3CA mutations. We find that CRC with AKT1 E17K mutation have a higher incidence of concurrent BRAF V600E mutations and mucinous histology in comparison to PIK3CA exon 10 mutated CRC. Our finding that PIK3CA exon 21 mutations have a higher prevalence of BRAF mutations and MSI-H status than PIK3CA exon 10 mutations is in agreement with recent reports from other groups. The prevalence of mucinous histology by PIK3CA mutation in our cohort was also in line with previous work. 4 The AKT1 mutations were concurrent with activating mutations in the RAS/ RAF pathway in the majority (85%) of cases, but were consistently mutually exclusive with PIK3CA mutations. The 3 cases of AKT1 E17K mutation that occurred in the absence of RAS/RAF mutations shared clinical features with other AKT1 mutant cases, including mucinous histology and microsatellite stable status.
The impact of AKT1 mutation on response to anti-EGFR therapy has not been previously studied.
Two of these 3 patients received anti-EGFR therapy (cetuximab), and both patients were resistant to this treatment. In comparison, of 8 patients with PIK3CA mutant and KRAS/ BRAF wild type CRC, 7 (88%) exhibited either tumor regression or stability when treated with anti-EGFR therapy, either alone or in combination with other therapies (table 2). A possible explanation for this different response to anti-EGFR therapy is that mutant PIK3CA leads to increased phosphorylation and dependence on ERK, which can be inhibited by cetuximab, while AKT1E17K mutation does not increase phosphorylation of ERK1/2. 15 While anti-EGFR therapy may not be an effective therapeutic option for these patients, targeted therapy against the AKT/mTOR pathway may be an emerging option in patients with metastatic disease.
Similar to PIK3CA H1047R/L/Y-mutated CRC, AKT1 E17K CRC showed a high rate of concurrent BRAF V600E mutation (28% for both PIK3CA exon 21 and AKT1 institutional cases), yet not as high of a rate of microsatellite instability (59% for PIK3CA exon 21 vs. 18% for AKT1). This relative enrichment of microsatellite-stable BRAF V600E mutants might account for the higher number of CRC with distant metastases (75.9% vs. 100%) seen in our AKT1 E17K CRC cohort as BRAF mutant microsatellite stable CRC has been associated with more aggressive disease and poor survival. Unlike AKT1 E17K and PIK3CA H1047R/L/Y-mutated CRC, PIK3CA R88Q, E542K, and E545K/G/D mutated CRC had a very low incidence of BRAF V600E co-mutation and relatively higher incidences of KRAS co-mutations. Recent work has shown that PIK3CA helical domain mutations in codons 542 and 545 require activation of the RAS-GTP pathway while kinase domain mutations in codon 1047 do not. 17 This may explain why we found that the PIK3CA exon 10 mutant cases had more RAS and fewer BRAF co-mutations in comparison to the PIK3CA exon 21 mutant cases.
These associations are in line with previous work by Day et al for PIK3CA E542, E545, and H1047 mutations. To our knowledge, this is also the first clinicopathologic report of PIK3CA R88Q in colorectal carcinoma. PIK3CA R88Q mutations have previously been reported in endometrial carcinoma. This mutation is thought to activate PI3K through the formation of a hydrogen bond with D746 that results in conformational change of the encoded protein and increased kinase activity. 18 While our numbers were too low for statistical analysis, the histologic and molecular profile of this subset seems more similar to helical domain (E542 and E545) mutant cases than kinase domain (H1047) mutant cases.
Our data also show that PTEN loss of expression and activating mutations within other areas of the PI3K mutation are not mutually exclusive as approximately 1/3 of all AKT1 or PIK3CA mutants lost PTEN expression. We found no difference in downstream activation of p-PRAS40 by immunohistochemistry between AKT1 E17K, PIK3CA helical domain, PIK3CA kinase domain, RAS, and BRAF mutants in this study.
A potential bias of our study is the preponderance of metastatic cases. In the vast majority of CRC submitted for clinical molecular analysis at our institution, testing is performed to determine candidacy for anti-EGFR therapy, and therefore, almost all of our cases (including all 17 AKT1 E17K) were late stage. Whether these results are applicable across all stages remains to be seen. Another shortfall pertains to the material tested: the technical sensitivity of our assay is 10%, thus false negatives due to between microsatellite instability testing by PCR and mismatch repair protein expression is very good, rare cases with mismatch repair abnormalities may be missed be either method.
In summary, the mutation AKT1 E17K in CRC is associated with mucinous morphology, pulmonary metastases, and co-mutation of BRAF V600E. They occur in mutual exclusivity of PIK3CA mutations. While AKT1 E17K mutations, even without concurrent BRAF or RAS mutations, seem to confer primary resistance to anti-EGFR therapy in our limited caseload, this observation warrants further studies. Additionally, it may serve as a targetable alteration in both RAS/RAF-mutated and RAS-RAF wild type CRC. 
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